FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, in particular to an antibody binding to human CSF-1R, and a pharmaceutical composition, containing the above antibody. In addition, a nucleic acid encoding the heavy and light chains of the above antibody is disclosed, expression vector and a host cell, containing aforesaid nucleic acid and a method for producing a recombinant antibody that binds to human CSF-1R, with its use. In addition, the use of the above antibody for the manufacture of drugs for the treatment of cancer, treatment of bone loss, preventing or treating metastases and inhibiting the cellular proliferation of CSF-1 ligand-dependent and / or ligand-independent cells are disclosed.
EFFECT: invention makes it possible to efficiently obtain and use antibodies against human CSF-1R, including for the manufacture of drugs for the treatment of cancer and inhibition of cell proliferation of CSF-1 cells.
19 cl, 7 tbl, 1 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES PRIMARILY BINDING TO EXTRACELLULAR DOMAIN 4 OF HUMAN CSF-1R, AND USING THEM | 2010 |
|
RU2565541C2 |
| ANTIBODY AGAINS CSF-1R | 2012 |
|
RU2621859C2 |
| CSF-1R ANTIBODY | 2009 |
|
RU2547586C2 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617971C2 |
| MACROPHAGE ACTIVATION MODULATION | 2012 |
|
RU2639553C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617966C2 |
| ANTIBODIES BOUND TO EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR (ALK) | 2007 |
|
RU2460540C2 |
| ANTIBODIES AGAINST G-CSFR AND USE THEREOF | 2012 |
|
RU2605595C2 |
| ANTIBODIES AGAINST HUMAN IL33R AND USE THEREOF | 2012 |
|
RU2597288C2 |
